Skip to main content
Clinical Trials/NCT02504242
NCT02504242
Unknown
Phase 3

A Multi-center, Comparative Clinical Trial to Evaluate the Efficacy and Safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion

BioAlpha Inc.0 sites128 target enrollmentApril 2015

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Transforaminal Lumbar Interbody Fusion
Sponsor
BioAlpha Inc.
Enrollment
128
Primary Endpoint
Bone Fusion With CT and Dynamic radiographs(X-ray)(post operative 48 weeks)
Last Updated
10 years ago

Overview

Brief Summary

A Randomized, Subject-Assessor Blind, Multi-center, Comparative Clinical Trial to evaluate the efficacy and safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion.

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
April 2017
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
BioAlpha Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The subject needs the infusion between the first lumbar vertebrato and the first ilium from those who require posterior spinal instrumentation and interbody fusion for the following reasons,
  • Spinal stenosis
  • Spinal disc herniation requiring broad laminectomy
  • Spondylolisthesis or spondylolysis
  • Recurrent herniated disc

Exclusion Criteria

  • Patients with BMD T-score \< -3.0
  • Women who are pregnant or plan to be pregnant within study period

Outcomes

Primary Outcomes

Bone Fusion With CT and Dynamic radiographs(X-ray)(post operative 48 weeks)

Time Frame: at 48 weeks after surgery

Similar Trials